Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Genetic Study of Schizophrenia
This study is currently recruiting participants.
Verified by National Institutes of Health Clinical Center (CC), June 2008
Sponsored by: National Institute of Mental Health (NIMH)
Information provided by: National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov Identifier: NCT00001486
  Purpose

This large ongoing study at NIMH investigates the neurobiology of schizophrenia by identifying susceptibility genes, evaluating their impact on brain function to better understand how to treat and prevent this illness.


Condition
Psychotic Disorder
Schizoaffective Disorder
Schizophrenia

MedlinePlus related topics: Psychotic Disorders Schizophrenia
U.S. FDA Resources
Study Type: Observational
Official Title: A Neurobiological Investigation of Patients With Schizophrenia Spectrum Disorders and Their Siblings

Further study details as provided by National Institutes of Health Clinical Center (CC):

Estimated Enrollment: 5400
Study Start Date: June 1995
Detailed Description:

Schizophrenia is a complex genetic disorder which likely involves many genes each producing a slight increase in risk. Finding weak acting genes in complex gentic disorders has been challenging and will likely require a number of approaches and large clinical samples. Several strategies have emerged recently that appear to markedly improve the power of genetic studies for detecting such genes. These include using association (rather than linkage) and using intermediate phenotypes in addition to DMS-IV diagnosis. We propose to take advantage of these techniques by studying quantitative traits related to schizophrenia in patients, siblings, and controls. We will employ an association design, rather than linkage. Traits will include quantifiable neurobiological variables that have been implicated previously as possible phenotypes related to schizophrenia. These include tests of attention and cognition, eye tracking, evoked potentials and a variety of parameters using brain imaging. We will use several statistical methods to show that specific genetic polymorphisms affect these phenotypes, including case control and family based association studies.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria
  • INCLUSION CRITERIA

Patients with schizophrenia, their biological siblings and their parents will be recruited through families of current or former patients at NIMH and physician and community organization referrals, The National Alliance for the Mentally Ill (NAMI), and other sources both locally and nationally.

To be eligible for this research study, patients must be between the ages of 18 and 55 and have a diagnosis of schizophrenia, schizoaffective disorder, psychosis N.O.S., or schizophreniform disorder.

To be eligible for this research study, siblings should be between 18 and 55, and have no major medical problems that may affect their brain including mental retardation or suffering from organic brain damage or neurological disease and have no significant history of alcoholism or substance abuse. Siblings that do not qualify for the 2-day or 1-day study, they may participate in the limited phenotyping arm or be included in as part of a trio (one parent, one sibling, one patient). All parents are eligible for the study.

To be eligible for this research study, healthy volunteers must be between the ages of 18 and 55. They will not be eligible if they have history of major medical problems that may affect their brain or if they have abused illicit drugs or alcohol for a significant amount of time. They may not be eligible for the extended part of the study if they have a first-degree relative with history of schizophrenia spectrum disorders. However, they may be included in the case control analyses and the limited phenotyping arm.

EXCLUSION CRITERIA

Persons who are mentally retarded, who suffer from organic brain damage, neurological disease, or have a significant history of alcoholism or substance abuse will not be included in the 2-day or 1-day study

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00001486

Contacts
Contact: CBDB (301) 435-8970 schizophrenia@intra.nimh.nih.gov

Locations
United States, Maryland
NAMI Research Institute Recruiting
Bethesda, Maryland, United States
Suburban Hospital Recruiting
Bethesda, Maryland, United States, 20814
Sponsors and Collaborators
  More Information

NIH Clinical Center Detailed Web Page  This link exits the ClinicalTrials.gov site

Publications:
Study ID Numbers: 950150, 95-M-0150
Study First Received: November 3, 1999
Last Updated: October 16, 2008
ClinicalTrials.gov Identifier: NCT00001486  
Health Authority: United States: Federal Government

Keywords provided by National Institutes of Health Clinical Center (CC):
Paranoia
Schizophrenic Research
Hallucinations
Delusions
Brain Scans
Negative Symptoms
Symptoms of Schizophrenia
Causes of Schizophrenia
Psychosis and Schizophrenia
Compensation
Schizophrenia
Schizoaffective Disorder
Psychosis
Manic-Depression

Study placed in the following topic categories:
Schizophrenia
Paranoid Disorders
Delusions
Depression
Mental Disorders
Bipolar Disorder
Hallucinations
Psychotic Disorders
Depressive Disorder
Schizophrenia and Disorders with Psychotic Features

Additional relevant MeSH terms:
Pathologic Processes
Disease

ClinicalTrials.gov processed this record on January 30, 2009